Investor Presentaiton
Major R&D Pipeline: 3ADCs
(US/EU/Asia) HER2+ BC 2L~/1L
DESTINY-Breast07
(US/EU/Asia) HER2 low BC
Chemo naïve/ post chemo
DESTINY-Breast08
Phase 1
(JP/US/EU/Asia) HER2+ GC combo, 2L~/1L
DESTINY-Gastric03
(EU/Asia) HER2+ NSCLC
(durvalumab combo) 1L
DESTINY-Lung03
(US/EU) BC, bladder (nivolumab combo)
(US/EU) BC, NSCLC
(pembrolizumab combo)
(US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(JP/US) NSCLC, TNBC, HR+ BC, SCLC,
urothelial, GC, esophageal, etc.
TROPION-PanTumor01
(CN) NSCLC, TNBC
TROPION-PanTumor02
(JP/US/EU/Asia) NSCLC
(w/o actionable mutation, pembrolizumab
combo)
TROPION-Lung02
(JP/US/EU) NSCLC
(w/o actionable mutation,
durvalumab combo)
TROPION-Lung04
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(JP/US/EU/Asia) NSCLC
Phase 2
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(CN) HER2+ GC 3L
DESTINY-Gastric06
Phase 3
(JP/US/EU/Asia) HER2+ BC 3L
DESTINY-Breast02
(JP/US/EU/Asia) HER2+ BC
post neoadjuvant
DESTINY-Breast05
(JP/US/EU/Asia) HER2 low BC
chemo naive
DESTINY-Breast06
(JP/US/EU/Asia) HER2+ BC 1L
DESTINY-Breast09
As of Jul 2022
Filed
(JP/US/EU/Asia) HER2+ BC 2L
DESTINY-Breast03
(EU) HER2+ GC 2L
DESTINY-Gastric02
(US) HER2 mutated NSCLC 2L~
DESTINY-Lung01
(JP/US/EU/Asia) HER2 low BC
post chemo
DESTINY-Breast04
(JP/US/EU) HER2+ NSCLC 2L~
DESTINY-Lung01
(JP/US/EU/Asia) HER2 mutated NSCLC 2L~
DESTINY-Lung02
(CN) HER2 mutated NSCLC 2L~
DESTINY-Lung05
(US/EU/Asia) NSCLC
(durvalumab combo) 2L~ HUDSON
(JP/US/EU) HER2+ CRC 3L
DESTINY-CRC01
(JP/US/EU/Asia) HER2+ CRC 3L
DESTINY-CRC02
(JP/US/EU/Asia) HER2+ BC
neoadjuvant
DESTINY-Breast11
(JP/US/Asia) HER2+ GC 2L
DESTINY-Gastric04
(JP/US/EU/Asia) NSCLC 1L
(w/ HER2 exon 19 or exon 20 mutation)
DESTINY-Lung04
(JP/US/EU/Asia) NSCLC 2/3L
TROPION-Lung01
(JP/US/EU/Asia) NSCLC (w/o actionable
mutation, pembro combo) 1L
TROPION-Lung08
(JP/US/EU/Asia) HR+ BC 2/3L
TROPION-Breast01
(JP/US/EU/Asia) TNBC 1L
TROPION-Breast02
ENHERTU®
Dato-DXd
HER3-DXd
(JP/US) EGFR mutated NSCLC
(osimertinib combo)
(JP/US) HER3+ BC
project in oncology that is planned to be submitted for approval in some
countries/regions based on the results of phase 2 trials
Breakthrough Designation (US)
BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell
lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer
(UP/US/EU/Asia)
HER2 mutated tumor
DESTINY-PanTumor01
(US/EU/Asia)
HER2 expressing tumor
DESTINY-PanTumor02
(JP/US/EU/Asia) NSCLC
(w/ actionable mutation)
TROPION-Lung05
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L (osimertinib combo)
ORCHARD
(JP/US/EU/Asia) EGFR mutated
NSCLC 3L
HERTHENA-Lung01
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L
HERTHENA-Lung02
Daiichi-Sankyo
41View entire presentation